UNSPSC 51333509: Clopipazan mesilate or mesylate

This classification denotes an antipsychotic agent with the molecular formula C19H18ClNO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4ZXX17M1C4, chemically known as piperidine 4-(2-chloro-9h-xanthen-9-ylidene)-1-methyl-, methanesulfonate, but more generally known as clopipazan mesylate, which bears US NIH Compound Identifier 43214. European Medicines Agency schedules clopipazan mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06741MIG.

Most nations, for tariff purposes, schedule clopipazan mesylate under HS 29349990. Clopipazan mesylate bears US NLM identifiers UMLS ID C2825692 and NCI Concept Code C81581. SMILES: CN1CCC(=C2C3CCCCC3OC4C2CC(CC4)CL)CC1.CS(=O)(=O)O.

UNSPSC 51333509 Clopipazan mesilate or mesylate is a Commodity code nominally tracking a specific pharmaceutical compound, but recent state and local procurement activity under this code shows little direct alignment with the named substance. The three most recent opportunities posted under 51333509 involve naloxone and drug deactivation systems (Seminole County, Florida), a direct-to-manufacturer prescription program request for information (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's nominal scope and the actual solicitations suggests either broad tagging of pharmaceutical procurement under this Commodity code or classification drift in state procurement systems. Issuing bodies include county health departments, state health agencies, and multi-state cooperative purchasing organizations.

Recent activity spans Florida, Texas, and Minnesota, with the Minnesota MMCAP solicitation (posted January 20, 2026, RFP due March 26, 2026) representing the largest in scope—seeking manufacturers to supply generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) to participating state and local facilities across multiple states including Oregon. Seminole County posted an invitation for bid (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas HHS Commission issued a request for information (RFI HHS0017013, posted April 3, 2026, response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. The Minnesota MMCAP award structure emphasizes price competitiveness (75 percent of evaluation weight), compliance with cGMP and Drug Supply Chain Security Act requirements, and maintenance of relationships with authorized wholesalers; contract performance penalties range from $200 to $1,500 per violation.